"Going global" is an important development strategy for Chinese biopharmaceutical companies to expand revenue, enhance competitiveness, and brand value. Chinese biopharmaceutical companies are heading towards the "deep sea" of internationalization, participating in global market competition and cooperation in all aspects through various means such as overseas investment in factories, establishment of research and development institutions, technology transfer, international registration and certification, integrating and optimizing resource allocation, and continuously improving their international innovation capabilities. How to grasp certainty in the wave of globalization, realize the grand vision of the internationalization strategy, seek new increments, is a major proposition for the Chinese biopharmaceutical industry today.
Frost & Sullivan hereby releases the 'Blue Book on the Current Situation and Trends of China's Biopharmaceuticals Going Global in 2024', aiming to track the process of Chinese biopharmaceuticals going global and sort out the driving factors for biopharmaceutical companies to accelerate their overseas layout. At the same time, the Blue Book will comprehensively and multi-dimensionally discuss and reflect on the development direction and value orientation of China's biopharmaceuticals going global, share relevant insights and analyses with industry stakeholders and investors, and jointly draw a blueprint for the international development of China's biopharmaceutical industry with all parties.
September 25, 2024. English version of the report.2024 Blue Book on Chinese Biopharmaceuticals Going Global: Current Status and TrendsIt has been published on the Frost & Sullivan global official website and is being synchronized with the launch on well-known global communication agencies (such as The Associated Press), mainstream financial media (such as Yahoo Finance), top North American financial media and websites (Business Insider, Dow Jones MarketWatch, Benzinga, Wall Street Insider, etc.), and top regional media around the world. Leveraging Frost & Sullivan's professional industry analysis, global distribution network, and industrial resource network, it effectively supports the internationalization strategy of Chinese biopharmaceutical enterprises.
